Dr. Paolo Tarantino reviewed key ongoing clinical trials at Harvard Breast Cancer Course – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: .
“Dr. Paolo Tarantino reviewed key ongoing clinical trials at today’s Harvard Breast Cancer Course.”
Paolo Tarantino shared this post, adding:
“ADCs, SERDs, IO and beyond: the therapeutic arsenal for BC is rapidly expanding.
Dozens of phase 3 trials are ongoing and will reshape the way we treat each BC subtype over the next years, with hopefully many more recurrences prevented and many life years gained for our patients.”
Sources: Dana-Farber’s Breast Oncology Center/X and Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023